MedTrace Logo

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

NCT06584812 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-01-06

No results posted yet for this study

Summary

This study is designed to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel.

Conditions

Interventions

DRUG

Tiprogrel

Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.

DRUG

Tiprogrel

Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.

DRUG

Clopidogrel

Period 3: Clopidogrel; loading dose of Clopidogrel followed by daily maintenance dose until Day 8.

DRUG

Ticagrelor

Period 4: Ticagrelor; loading dose of Ticagrelor followed by daily maintenance dose until Day 8.

Sponsors & Collaborators

  • Tianjin Institute of Pharmaceutical Research Co., Ltd

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-09
Primary Completion
2024-12-05
Completion
2024-12-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06584812 on ClinicalTrials.gov